lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid]
lansoprazole
RxCUI: 206206
What the CMS Formulary Data Shows for lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid]
Per the CMS 2026 Part D formulary file, lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] (RxNorm concept RXCUI 206206, generic name lansoprazole) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 100% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 303,222 Part D beneficiaries filled lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] in 2023, with total plan-and-beneficiary spending of $57,025,404 and an average per-beneficiary annual cost of $188.06. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 100% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 303,222
- Total spending
- $57,025,404
- Avg per beneficiary
- $188.06
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] covered by Medicare Part D?
Yes, lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] on Medicare Part D plans?
lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] require prior authorization?
0% of Part D formularies require prior authorization for lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid]. Step therapy: 100%. Quantity limits: 100%.
How much does Medicare spend on lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid]?
In 2023, total Medicare Part D spending on lansoprazole 30 MG Delayed Release Oral Capsule [Prevacid] was $57,025,404, covering 303,222 beneficiaries. The average spend per beneficiary was $188.06.
Read our methodology - how this data is sourced, computed, and verified.